CN107847508B - 基于卡铂的共晶的药物组合物及其用途 - Google Patents

基于卡铂的共晶的药物组合物及其用途 Download PDF

Info

Publication number
CN107847508B
CN107847508B CN201680035450.1A CN201680035450A CN107847508B CN 107847508 B CN107847508 B CN 107847508B CN 201680035450 A CN201680035450 A CN 201680035450A CN 107847508 B CN107847508 B CN 107847508B
Authority
CN
China
Prior art keywords
crystal
nmp
cbp
cancer
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680035450.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107847508A (zh
Inventor
刘晓忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syn Nat Products Enterprise LLC
Original Assignee
Syn Nat Products Enterprise LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn Nat Products Enterprise LLC filed Critical Syn Nat Products Enterprise LLC
Publication of CN107847508A publication Critical patent/CN107847508A/zh
Application granted granted Critical
Publication of CN107847508B publication Critical patent/CN107847508B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680035450.1A 2015-06-19 2016-06-20 基于卡铂的共晶的药物组合物及其用途 Active CN107847508B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182142P 2015-06-19 2015-06-19
US62/182,142 2015-06-19
PCT/US2016/038340 WO2016205785A1 (en) 2015-06-19 2016-06-20 Pharmaceutical composition of carboplatin based co-crystals and use thereof

Publications (2)

Publication Number Publication Date
CN107847508A CN107847508A (zh) 2018-03-27
CN107847508B true CN107847508B (zh) 2020-10-02

Family

ID=57546414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680035450.1A Active CN107847508B (zh) 2015-06-19 2016-06-20 基于卡铂的共晶的药物组合物及其用途

Country Status (9)

Country Link
US (1) US10421770B2 (enExample)
EP (1) EP3297636B1 (enExample)
JP (1) JP6768716B2 (enExample)
KR (1) KR20180018800A (enExample)
CN (1) CN107847508B (enExample)
AU (1) AU2016279099B2 (enExample)
BR (1) BR112017027285A2 (enExample)
CA (1) CA2988992A1 (enExample)
WO (1) WO2016205785A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297624B1 (en) * 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
AU2016279099B2 (en) 2015-06-19 2021-09-23 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN108697093A (zh) 2015-06-19 2018-10-23 新纳特产品公司 含卡铂的组合物及其用途
EP3297640A4 (en) 2015-06-25 2019-01-02 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558909A (zh) * 2001-11-30 2004-12-29 超分子碳铂衍生物、其制备方法、包含该衍生物为活性成分的药物组合物及其应用
JP2007524596A (ja) * 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2008140850A1 (en) * 2007-03-02 2008-11-20 Novartis Ag Solid forms of a raf kinase inhibitor
WO2009091103A1 (en) * 2008-01-14 2009-07-23 Korea Advanced Institute Of Science And Technology Complex of biopolymers and insoluble biomolecules, and manufacturing method thereof
JP2011256175A (ja) * 2003-12-09 2011-12-22 Medcrystalforms Llc 活性剤との混合相共結晶の調製方法
CN104122280A (zh) * 2014-08-13 2014-10-29 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发（苏州）有限公司 超分子抗癌药物双环铂的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922689A (en) 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6297245B1 (en) 1998-08-04 2001-10-02 Unitech Pharmaceuticals Cisplatin and folic acid administered to treat breast cancer
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(ｉｖ)착제 및 그 제조방법
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RS20050106A (sr) 2002-08-19 2007-11-15 Pfizer Products Inc., Kombinovana terapija hiperproliferativnih bolesti
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
DE602004015811D1 (de) 2003-08-13 2008-09-25 Univ South Florida Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
KR101345002B1 (ko) * 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
CN100500219C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种含铂类化合物的抗实体肿瘤药物组合物
JP2009525273A (ja) 2006-01-30 2009-07-09 プラットコー テクノロジーズ （プロプライエタリー） リミテッド 白金（ｉｉ）錯体の調製
US20080063642A1 (en) 2006-08-02 2008-03-13 Adelman Daniel C Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CA2736732A1 (en) 2008-09-15 2010-03-18 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5179628B2 (ja) * 2011-07-15 2013-04-10 ユニーテック株式会社 ４価白金錯体及びそれを含む医薬組成物
US9220705B2 (en) * 2013-03-07 2015-12-29 James David Hoeschele Method of treating colorectal cancer
PL3424920T3 (pl) * 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
CN104127402B (zh) 2014-08-15 2019-08-30 北京默加农生物技术发展有限公司 双环铂在制备抗病毒药物和抗菌药物中的应用
EP3280408B1 (en) 2015-04-10 2019-10-23 Syn-Nat Products Enterprise LLC Process for the preparation of dicycloplatin
AU2016250616B2 (en) 2015-04-22 2021-01-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
AU2016279099B2 (en) 2015-06-19 2021-09-23 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN108697093A (zh) 2015-06-19 2018-10-23 新纳特产品公司 含卡铂的组合物及其用途
EP3297640A4 (en) 2015-06-25 2019-01-02 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558909A (zh) * 2001-11-30 2004-12-29 超分子碳铂衍生物、其制备方法、包含该衍生物为活性成分的药物组合物及其应用
JP2007524596A (ja) * 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2011256175A (ja) * 2003-12-09 2011-12-22 Medcrystalforms Llc 活性剤との混合相共結晶の調製方法
WO2008140850A1 (en) * 2007-03-02 2008-11-20 Novartis Ag Solid forms of a raf kinase inhibitor
WO2009091103A1 (en) * 2008-01-14 2009-07-23 Korea Advanced Institute Of Science And Technology Complex of biopolymers and insoluble biomolecules, and manufacturing method thereof
CN104122280A (zh) * 2014-08-13 2014-10-29 北京默加农生物技术发展有限公司 一种以双环铂为有效成分的药物的检测方法
CN104693245A (zh) * 2015-03-13 2015-06-10 卓越同达医药科技开发（苏州）有限公司 超分子抗癌药物双环铂的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin. Synthesis, Structures, and Cytotoxicity;Cui, HL et al.;《Inorganic Chemistry》;20140325;第53卷(第7期);第3371-3384页 *
Synthesis, crystal structures, DNA binding and cytotoxicity of two novel platinum(II) complexes containing 2-(hydroxymethyl)pyridine and pyridine-2-carboxylate ligands;Icsel, C et al.;《Bioorganic & Medicinal Chemistry Letters》;20130208;第23卷(第7期);第2117-2122页 *
超分子抗癌药物双环铂的结构研究;杨旭清 等;《中国科学: 化学》;20101231;第40卷(第5期);第485-491页 *

Also Published As

Publication number Publication date
US10421770B2 (en) 2019-09-24
AU2016279099B2 (en) 2021-09-23
EP3297636B1 (en) 2021-02-17
WO2016205785A1 (en) 2016-12-22
CA2988992A1 (en) 2016-12-22
KR20180018800A (ko) 2018-02-21
CN107847508A (zh) 2018-03-27
EP3297636A4 (en) 2018-11-14
JP2018524320A (ja) 2018-08-30
JP6768716B2 (ja) 2020-10-14
EP3297636A1 (en) 2018-03-28
AU2016279099A1 (en) 2018-01-04
US20180179240A1 (en) 2018-06-28
BR112017027285A2 (pt) 2018-09-11

Similar Documents

Publication Publication Date Title
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
CN108135877B (zh) 药物共晶及其用途
JP5860872B2 (ja) ホスファプラチン、及び癌治療のためのそれらの使用
CN107847508B (zh) 基于卡铂的共晶的药物组合物及其用途
CN102438612A (zh) 腈衍生物及其药学用途与组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant